Palvella Therapeutics, Inc. (PVLA)Healthcare | Biotechnology | Wayne, United States | NasdaqCM
130.01 USD
+5.83
(4.695%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 130.01 Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:31 p.m. EDT
PVLA has shown strong recent momentum with a price surge and positive news, but fundamentals remain weak with negative earnings and high debt. Short-term traders may find opportunities in the current volatility, but long-term investors should be cautious due to the company's financial risks and lack of dividend history. The stock is currently in a volatile phase with mixed signals from options activity. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.152042 |
| AutoTheta | 0.187260 |
| MSTL | 0.216194 |
| AutoETS | 0.219039 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.229 |
| Excess Kurtosis | -1.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 65.729 |
| Market Cap | 1,860,918,784 |
| Forward P/E | -19.76 |
| Website | https://palvellatx.com |
As of April 11, 2026, 1:31 p.m. EDT: Options activity indicates a mix of bullish and bearish sentiment. Calls show significant positioning in the upper range (e.g., strikes at 160, 170), suggesting potential for upward movement. However, puts also show notable activity, particularly in the lower range, indicating some bearish sentiment. The IV spikes and high OI in certain strikes suggest volatility and uncertainty, with traders potentially anticipating a range-bound or directional move.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.108448 |
| Address1 | 353 W. Lancaster Avenue |
| Address2 | Suite 200 |
| All Time High | 780.0 |
| All Time Low | 6.2 |
| Ask | 131.1 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 230,770 |
| Average Daily Volume3 Month | 320,506 |
| Average Volume | 320,506 |
| Average Volume10Days | 230,770 |
| Bid | 128.73 |
| Bid Size | 1 |
| Board Risk | 4 |
| Book Value | 2.26 |
| City | Wayne |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 130.01 |
| Current Ratio | 5.2 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 131.6 |
| Day Low | 125.4 |
| Debt To Equity | 65.729 |
| Display Name | Palvella Therapeutics |
| Earnings Call Timestamp End | 1,774,960,200 |
| Earnings Call Timestamp Start | 1,774,960,200 |
| Earnings Timestamp | 1,774,960,200 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 1,821,329,792 |
| Eps Current Year | -5.14 |
| Eps Forward | -6.57818 |
| Eps Trailing Twelve Months | -3.71 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 115.3246 |
| Fifty Day Average Change | 14.685394 |
| Fifty Day Average Change Percent | 0.12733965 |
| Fifty Two Week Change Percent | 410.8448 |
| Fifty Two Week High | 151.18 |
| Fifty Two Week High Change | -21.169998 |
| Fifty Two Week High Change Percent | -0.14003174 |
| Fifty Two Week Low | 20.2 |
| Fifty Two Week Low Change | 109.81 |
| Fifty Two Week Low Change Percent | 5.436138 |
| Fifty Two Week Range | 20.2 - 151.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,420,209,000,000 |
| Float Shares | 9,270,957 |
| Forward Eps | -6.57818 |
| Forward P E | -19.763824 |
| Free Cashflow | -18,630,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17661 |
| Held Percent Institutions | 0.72069 |
| Implied Shares Outstanding | 14,313,659 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,713,830,400 |
| Last Split Factor | 1:80 |
| Long Business Summary | Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania. |
| Long Name | Palvella Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,860,918,784 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_534271315 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -41,715,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,856,767,845 |
| Number Of Analyst Opinions | 15 |
| Open | 126.2 |
| Operating Cashflow | -25,006,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 484 253 1461 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 130.01 |
| Post Market Time | 1,776,458,402 |
| Previous Close | 124.18 |
| Price Eps Current Year | -25.293774 |
| Price Hint | 2 |
| Price To Book | 57.526546 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.111 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 5.82999 |
| Regular Market Change Percent | 4.69479 |
| Regular Market Day High | 131.6 |
| Regular Market Day Low | 125.4 |
| Regular Market Day Range | 125.4 - 131.6 |
| Regular Market Open | 126.2 |
| Regular Market Previous Close | 124.18 |
| Regular Market Price | 130.01 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 301,992 |
| Return On Assets | -0.32648998 |
| Return On Equity | -0.92096 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 14,313,659 |
| Shares Percent Shares Out | 0.1521 |
| Shares Short | 2,176,586 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,744,863 |
| Short Name | Palvella Therapeutics, Inc. |
| Short Percent Of Float | 0.1765 |
| Short Ratio | 7.5 |
| Source Interval | 15 |
| State | PA |
| Symbol | PVLA |
| Target High Price | 270.0 |
| Target Low Price | 205.0 |
| Target Mean Price | 230.06667 |
| Target Median Price | 225.0 |
| Total Cash | 57,982,000 |
| Total Cash Per Share | 4.051 |
| Total Debt | 18,393,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.71 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 80.797775 |
| Two Hundred Day Average Change | 49.21222 |
| Two Hundred Day Average Change Percent | 0.6090789 |
| Type Disp | Equity |
| Volume | 301,992 |
| Website | https://palvellatx.com |
| Zip | 19,087 |